Search research articles
Contact Us
Filters
Showing results (181-190 of 487) with videos related to
Page
of 49
Sort By:
Cancers
|
March 22, 2020
Cancer Genetics and Therapeutic Opportunities in Urologic Practice
Jacob J Adashek, Alex Leonard, Jason Roszik, et al.
Molecular Cancer Therapeutics
|
April 12, 2022
Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600-Mutant Tumors
Jacob J Adashek, Arjun K Menta, Neha K Reddy, et al.
Oncoscience
|
September 22, 2023
Activity of pazopanib in <i>EWSR1-NFATC2</i> translocation-associated bone sarcoma
Mohamed A Gouda, Maria A Zarzour, Ara A Vaporciyan, et al.
Oncotarget
|
January 8, 2014
A novel immunomodulatory molecularly targeted strategy for refractory Hodgkin's lymphoma
Vivek Subbiah, Robert E Brown, Mary F McGuire, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 29, 2011
Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside
Vivek Subbiah, John Slopis, David S Hong, et al.
Molecular Cancer Therapeutics
|
September 8, 2021
Hallmarks of RET and Co-occuring Genomic Alterations in <i>RET</i>-aberrant Cancers
Jacob J Adashek, Aakash P Desai, Alexander Y Andreev-Drakhlin, et al.
Plos One
|
August 8, 2013
Morphoproteomic profiling of the mammalian target of rapamycin (mTOR) signaling pathway in desmoplastic small round cell tumor (EWS/WT1), Ewing's sarcoma (EWS/FLI1) and Wilms' tumor(WT1)
Vivek Subbiah, Robert E Brown, Yunyun Jiang, et al.
Thyroid Research
|
August 13, 2023
Challenges in the care of patients with RET-altered thyroid cancer: a multicountry mixed-methods study
Suzanne Murray, Vivek Subbiah, Steven I Sherman, et al.
Med (New York, N.Y.)
|
January 29, 2026
Precision oncology in rare tumors: Have the orphans been adopted?
Hiba Mechahougui, Alex Friedlaender, Kıvanç Görgülü, et al.
ESMO Open
|
April 10, 2019
Development of sodium fluoride PET response criteria for solid tumours (NAFCIST) in a clinical trial of radium-223 in osteosarcoma: from RECIST to PERCIST to NAFCIST
Kalevi Kairemo, Eric M Rohren, Pete M Anderson, et al.
Page
of 49
Search research articles
Search
Showing results (181-190 of 487) with videos related to
Sort By:
Page
of 49
Cancers
|
March 22, 2020
Cancer Genetics and Therapeutic Opportunities in Urologic Practice
Jacob J Adashek, Alex Leonard, Jason Roszik, et al.
Molecular Cancer Therapeutics
|
April 12, 2022
Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600-Mutant Tumors
Jacob J Adashek, Arjun K Menta, Neha K Reddy, et al.
Oncoscience
|
September 22, 2023
Activity of pazopanib in <i>EWSR1-NFATC2</i> translocation-associated bone sarcoma
Mohamed A Gouda, Maria A Zarzour, Ara A Vaporciyan, et al.
Oncotarget
|
January 8, 2014
A novel immunomodulatory molecularly targeted strategy for refractory Hodgkin's lymphoma
Vivek Subbiah, Robert E Brown, Mary F McGuire, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 29, 2011
Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside
Vivek Subbiah, John Slopis, David S Hong, et al.
Molecular Cancer Therapeutics
|
September 8, 2021
Hallmarks of RET and Co-occuring Genomic Alterations in <i>RET</i>-aberrant Cancers
Jacob J Adashek, Aakash P Desai, Alexander Y Andreev-Drakhlin, et al.
Plos One
|
August 8, 2013
Morphoproteomic profiling of the mammalian target of rapamycin (mTOR) signaling pathway in desmoplastic small round cell tumor (EWS/WT1), Ewing's sarcoma (EWS/FLI1) and Wilms' tumor(WT1)
Vivek Subbiah, Robert E Brown, Yunyun Jiang, et al.
Thyroid Research
|
August 13, 2023
Challenges in the care of patients with RET-altered thyroid cancer: a multicountry mixed-methods study
Suzanne Murray, Vivek Subbiah, Steven I Sherman, et al.
Med (New York, N.Y.)
|
January 29, 2026
Precision oncology in rare tumors: Have the orphans been adopted?
Hiba Mechahougui, Alex Friedlaender, Kıvanç Görgülü, et al.
ESMO Open
|
April 10, 2019
Development of sodium fluoride PET response criteria for solid tumours (NAFCIST) in a clinical trial of radium-223 in osteosarcoma: from RECIST to PERCIST to NAFCIST
Kalevi Kairemo, Eric M Rohren, Pete M Anderson, et al.
Page
of 49